Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Transcode Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Transcode Therapeutics, Inc.

RNAZ

Transcode Therapeutics, Inc.

About Transcode Therapeutics, Inc.

TransCode Therapeutics develops RNA-based oncology therapeutics with a proprietary delivery platform targeting undruggable genetic markers in cancer. Its focus includes metastatic tumors, utilizing modular design and imaging-guided delivery to enhance targeting, stability, and efficacy. The company’s lead candidate, TTX-MC138, targets microRNA-10b to inhibit metastasis across multiple cancers, advancing through clinical trials to offer precision, potentially transformative cancer treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Transcode Therapeutics, Inc.

1
1
Transcode Therapeutics, Inc. Transcode Therapeutics Reports $19.5 Million Net Loss and Increased R&D Expenses in Latest 10-Q

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Transcode Therapeutics, Inc. Transcode Therapeutics Reports $34.7 Million Net Loss for 2025, Driven by Increased Expenses

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Transcode Therapeutics, Inc. TransCode Therapeutics Reports Increased Losses and Strategic Acquisition in Latest 10-Q Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Transcode Therapeutics, Inc. TransCode Therapeutics Reports Q2 2025 Financial Results with $4.3M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Transcode Therapeutics, Inc. TransCode Therapeutics Reports Increased Losses and Financial Challenges in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Transcode Therapeutics, Inc. TransCode Therapeutics Reports $16.8 Million Net Loss for 2024, Highlights Clinical Trial Progress

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Transcode Therapeutics, Inc. TransCode Therapeutics Reports Financial Results, Operating Loss, and Cash Decline Amid Ongoing Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments